Search results
Showing 631 to 645 of 766 results for mental health
Smoking: cessation success in people with bipolar, schizophrenia and other psychoses (IND271)
This indicator covers the percentage of patients with schizophrenia, bipolar affective disorder and other psychoses recorded as current smokers in the previous 13 to 48 months, who were recorded as ex-smokers in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
Depression and anxiety: review within 10 to 35 days (IND104)
This indicator covers the percentage of patients with a new diagnosis of depression in the preceding 1 April to 31 March who have been reviewed within 10 to 35 days of the date of diagnosis. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM50
This guideline covers the diagnosis and management of diverticular disease in people aged 18 years and over. It aims to improve diagnosis and care and help people get timely information and advice, including advice about symptoms and when to seek help.
This guideline covers the diagnosis and management of gout. It includes recommendations on diagnosing gout, managing flares, long-term management of gout and referral to specialist services.
Evidence-based recommendations on vortioxetine (Brintellix) for treating major depressive episodes in adults.
This guideline covers care for people with a family history of breast, ovarian or another related (prostate or pancreatic) cancer. It aims to improve the long-term health of these families by describing strategies to reduce the risk of and promote early detection of breast cancer (including genetic testing and mammography). It also includes advice on treatments (tamoxifen, raloxifene) and surgery (mastectomy).
This guideline covers care and management for adults (aged 18 and over) with type 2 diabetes. It focuses on patient education, dietary advice, managing cardiovascular risk, managing blood glucose levels, and identifying and managing long-term complications.
Endoscopic radiofrequency ablation for gastro-oesophageal reflux disease (IPG461)
Evidence-based recommendations on endoscopic radiofrequency ablation for gastro-oesophageal reflux disease. This involves using heat from electrodes to change the tissues in the oesophagus, with the aim of reducing symptoms.
This guideline covers assessing and managing chronic hepatitis B in children, young people and adults. It aims to improve care for people with hepatitis B by specifying which tests and treatments to use for people of different ages and with different disease severities.
Evidence-based recommendations on nivolumab (Opdivo) as a possible treatment for completely resected oesophageal or gastro-oesophageal junction cancer in adults.
This quality standard covers the additional antenatal care for women who are pregnant with twins or triplets that is offered alongside routine antenatal care. It describes high-quality care in priority areas for improvement.
View quality statements for QS46Show all sections
Sections for QS46
- Quality statements
- Quality statement 1: Determining chorionicity and amnionicity
- Quality statement 2: Labelling the fetuses
- Quality statement 3: Composition of the multidisciplinary core team
- Quality statement 4: Care planning
- Quality statement 5: Monitoring for fetal complications
- Quality statement 6: Involving a consultant from a tertiary level fetal medicine centre
- Quality statement 7: Advice and preparation for preterm birth
are in evidence review F: interventions to promote physical, mental, and emotional health and wellbeing of looked-after...
Evidence-based recommendations on imlifidase (Idefirix) for desensitisation treatment before kidney transplant in people with chronic kidney disease.
Oesophago-gastric cancer: assessment and management in adults (NG83)
This guideline covers assessing and managing oesophago-gastric cancer in adults, including radical and palliative treatment and nutritional support. It aims to reduce variation in practice through better organisation of care and support, and improve quality of life and survival by giving advice on the most suitable treatments depending on cancer type, stage and location.
Ozanimod for treating moderately to severely active ulcerative colitis (TA828)
Evidence-based recommendations on ozanimod (Zeposia) for treating moderately to severely active ulcerative colitis in adults when conventional or biological treatments cannot be tolerated or are not working well enough.